Bitwise Crypto Industry Innovators ETF vs ResMed Inc. — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $22.36, while ResMed Inc. trades at $222.39 (market cap $31.92B). The key difference: ResMed Inc. pays a 1.2% dividend while Bitwise Crypto Industry Innovators ETF pays none. Which is the better fit depends on your goals.
| BITQ | RMD | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $30.43 | $293.73 |
52-Week Low | $16.74 | $182.82 |
Market Cap | — | $31.92B |
Enterprise Value | — | $31.28B |
Dividend Yield | — | 1.2% |
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $22.88, up 1.42% today, but faces strong technical headwinds with 17 sell signals versus 0 buy signals across moving averages and oscillators. The stock shows bearish momentum with key resistance at $23 and support at $22. Financial metrics remain unavailable in current data, requiring verification through SEC filings.
The technical outlook appears bearish with weak momentum indicators. Investment opportunity depends on upcoming earnings clarity and institutional positioning. Primary risks include market volatility and lack of visible fundamental support until financial disclosures are updated.
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
Trailing returns across standard periods
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →